What Eli Lilly actually looks for
Eli Lilly, headquartered in Indianapolis, Indiana, built its long history on insulin products like Humalog and has become one of the most valuable pharmaceutical companies in the world on the back of its GLP-1 drugs, Mounjaro (tirzepatide) for diabetes and Zepbound for weight loss, which compete directly with Novo Nordisk's Ozempic and Wegovy. This GLP-1 boom has created real manufacturing scale challenges, with Lilly investing heavily in new production capacity to meet demand that has repeatedly outstripped supply, so interviewers in operations, supply chain, and manufacturing roles should expect detailed questions about scaling production reliably. Lilly also has a growing Alzheimer's franchise with Kisunla (donanemab), reflecting a broader push into neuroscience alongside its diabetes and obesity strength. Given the intense competitive and media attention on GLP-1 drugs, expect interviewers to test whether you can discuss the science and business soberly rather than hype-driven.
Common questions and how to answer them
How would you address a persistent supply shortage for a high-demand drug like Zepbound? Talk through manufacturing capacity investment, prioritization frameworks for allocating limited supply, and how you'd communicate transparently with patients and providers during a shortage. How does Lilly differentiate Mounjaro and Zepbound from Novo Nordisk's competing GLP-1 drugs? A solid answer references tirzepatide's dual mechanism (acting on both GIP and GLP-1 receptors) as a real clinical differentiator, not just brand positioning. What ethical considerations come with a drug this in-demand and expensive? Show you can hold access and affordability concerns alongside the business reality of R&D costs and investor expectations, without dismissing either side. In every case, be precise about tirzepatide's mechanism and Lilly's manufacturing challenges, since vague enthusiasm about GLP-1 drugs without technical or operational grounding reads as surface-level knowledge.
How to prepare
Understand tirzepatide's mechanism well enough to explain simply why Mounjaro and Zepbound are seen as differentiated from other GLP-1 drugs on the market. Follow recent news on Lilly's manufacturing capacity expansion, since supply constraints have been a real, ongoing operational story rather than a one-time issue. If interviewing for a commercial or access role, be ready to discuss insurance coverage and affordability challenges around GLP-1 drugs, since this is a genuine point of public and regulatory scrutiny. Expect operations and supply chain interviews to include scenario questions about prioritizing limited drug supply across patient populations, since this has been a real, recurring operational challenge for Lilly.